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Abstract
Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease
(CKD). It is metabolized by cytochrome P450 2C9 to active E-3174. Single nucleotide
polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits. The study
aims were to determine whether CYP2C9 variant alleles (*2 and *3) altered urinary protein excretion,
glomerular filtration rate, and blood pressure in Caucasians prescribed losartan. Differences between
baseline and six-month follow-up outcomes were compared by CYP2C9 genotypes in 59 patients
using unpaired T-test or Mann Whitney U test. Primary renal disease patients had a trend toward less
favorable antiproteinuric response (−31.7±156 vs −125±323%; p=0.123) when carrying variant
alleles. Patients with secondary renal diseases had less favorable diastolic blood pressure (9.8±16.0
mm Hg vs −3.2±10.6 mm Hg; p=0.043) and systolic blood pressure (16.2±27.1 mm Hg vs −5.5±17.5
mm Hg; p=0.044) with CYP2C9 variants. Preliminary results suggest a possible influence of
CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan.
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Introduction
The primary strategies to slow or prevent progression of chronic kidney disease (CKD) include
reduction in blood pressure and control of urinary protein excretion.[1] Proteinuria, in addition
to being a risk factor for CKD progression also predicts cardiovascular outcomes. [2,3] Timely
reduction of proteinuria, i.e. within the first 6–12 months of treatment is deemed crucial. [3]
Treatment strategies for controlling proteinuria as well as reducing blood pressure in CKD
include angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors. [4]
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Patient-related factors that may predict the likelihood of pharmacodynamic outcomes would
be helpful for individualizing treatment strategies and possibly improving kidney outcomes.
Losartan is an angiotensin receptor blocker metabolized by cytochrome P450 2C9 (CYP2C9).
Other CYP2C9 substrates include S-warfarin, phenytoin, torsemide, glipizide, nonsteroidal
anti-inflammatory agents, and irbesartan. Point mutations or single nucleotide polymorphisms
in the CYP2C9 gene have been identified. The common coding mutations in CYP2C9 are
CYP2C9*2 (Arg144Cys), and CYP2C9*3 (Ile359Leu). [5,6] Approximately two-thirds of the
Caucasian population express the wild-type genotype (CYP2C9*1/*1), one-third express either
the *1/*2 or *1/*3 genotype, and less than 2.5% of individuals express the *2 /*2, *2/*3, and
*3/*3 genotypes. [6] The frequency of the variant alleles (*2 and *3) however, are lower (<
5%) in African-American and Asian populations, with greater than 95% of these individuals
expressing the wild-type genotype. [6] Both in vitro and in vivo investigations suggest that
CYP2C9*2 and/or CYP2C9*3 alleles result in decreased catalytic activity for losartan when
compared to homozygosity for the *1 allele. [7,8] Several additional rare coding alleles of
CYP2C9 have been identified in Caucasians, although their drug metabolizing phenotypes have
not yet been adequately examined in vivo. [9,10]
Given the knowledge concerning CYP2C9 genotype and warfarin [11,12], we were interested
in evaluating the effects of CYP2C9 genotype on outcomes to losartan therapy in CKD patients.
Unlike warfarin which is metabolized to the minimally or inactive alcohol and hydroxyl
metabolites, losartan has a highly active 5-carboxylic acid metabolite, E-3174. [13] A reduced
CYP2C9 activity phenotype for losartan as described by the *2 and *3 genetic variants would
reduce the formation of E-3174, possibly shifting losartan’s metabolism to inactive metabolites
via other oxidative routes or glucuronidation. Individuals with the *2 or *3 variant alleles could
have attenuated clinical responses. Our pilot study was designed to evaluate the effect of
CYP2C9 genotype on clinical responses to losartan therapy in Caucasian individuals with CKD
due to primary and secondary etiologies. Specifically, we were interested in determining
pharmacodynamic changes in urinary protein excretion, glomerular filtration rate (eGFR),
systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with primary and
secondary kidney diseases according to the presence or absence of variant CYP2C9 *2 and/or
*3 alleles.
Materials and Methods
Subjects and Clinical Data
The study was approved by the University Investigational Review Board (IRB) and complied
with Health Insurance Portability and Accountability Act (HIPPA) regulations and the
Declaration of Helsinki. Fifty-nine Caucasian subjects with CKD and prescribed losartan were
targeted for enrollment from the outpatient Nephrology clinic. Patients were subsequently
classified as having a primary renal disease (e.g. glomerulonephritis) or a secondary renal
disease (e.g. type II diabetes mellitus, and/or hypertension). Additional inclusion criteria for
study participation were 1) proteinuria, with or without renal function decline as assessed by
eGFR [14], 2) documented date of losartan therapy initiation and data on drug dosing, 3)
documented laboratory data, including urinary protein excretion and serum creatinine, and 4)
documented blood pressure recordings from 30 days prior to the start of losartan initiation
through six months of follow-up. Both laboratory and blood pressure recordings were required
to be available from the 30 days prior to losartan commencement and six month time period.
Exclusion criteria included a history of significant non-compliance with prescribed
medications, receiving hemodialysis or peritoneal dialysis for Stage 5 CKD, and receiving
potential CYP2C9 inducers or inhibitors.
Joy et al. Page 2













Medical records were reviewed for demographics, blood pressure measurements, and
laboratory parameters of interest (serum creatinine, urinary protein excretion or a urinary
protein to creatinine ratio, eGFR) from losartan initiation and until 6 months of follow-up.
Blood pressure measurements in the clinic are routinely performed in a sitting position after
having the patient rest for five minutes. The measurement is repeated at least once for
verification of the result. Subject medications were reviewed and concomitant medications
with an indication for hypertension and diuresis were recorded. Medication lists were also
reviewed to identify any potential CYP2C9-mediated interactions (i.e. drugs that inhibit or
induce CYP2C9). Potential CYP2C9 inhibitors that were excluded were amiodarone,
fluconazole, fluvoxamine, gemfibrozil, metronidazole, phenytoin, sulfamethoxazole,
tamoxifen, valproic acid, sertraline, isoniazid, oral contraceptives, and zafirlukast. Potential
CYP2C9 inducers that were excluded were rifampin, St John’s Wort, and barbiturates.
Evaluation of Single Nucleotide Polymorphisms
A 5 mL whole blood sample was collected into an EDTA containing vacutainer and genomic
DNA was isolated using a Flexigene Qiagen kit (Qiagen, Inc., Valencia, CA, USA)
Pyrosequencing assays were used to determine the presence of the CYP2C9 *1 (wild-type),
*2 and *3 alleles as described by Limdi et al[11]. Briefly, amplification reactions of genomic
DNA were generated for pyrosequencing by using 10–30 ng DNA in 40 µl volumes.
Biotinylated forward primers and standard reverse primers (Eurogentec, San Diego, CA) in
the amount of 0.2 pm/µl each were added and combined with final concentrations of 2mM
MgCl2 , 0.5 mM dNTPs, 1× PCR buffer and 1 unit AmpliTaq Gold (Applied Biosystems,
Foster City, CA). The reactions were cycled with an initial denaturation of 95°C for 8 min
followed by 45 cycles of 95°C for 15 sec, 56°C for 30 sec, 72°C for 15 sec and final extension
for 5 min at 72°C on a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA).
The primers for amplifcation of CYP2C9*2 were 5'-BT-
AAACAGAGACTTACAGAGCTC-3' (BT: biotinylated) and 5'-
CTAACAACCAGACTCATAATG-3', while the sequencing primer was 5'-
GGGCTTCCTCTTGAAC-3'. For the CYP2C9*3 allele, the forward and reverse amplification
primers were 5’-BT-TGCACGAGGTCCAGAGAT-3' and 5'-
GATACTATGAATTTGGGACTTC-3', while the sequencing primer was 5'-
GCTGGTGGGGAGAAG-3'.
The biotinylated reaction products were immobilized on 3 ul (10 ug/ul) Streptavidin-Sepharose
High Performance beads (Amersham Biosciences, Piscataway, NJ) in the presence of a 1×
final concentration of Binding Buffer (Biotage, Foxboro, MA) by mixing for 10 min at room
temperature. Biotinylated DNA strand separation was accomplished by using the Vacuum Prep
Tool to capture beads and process through washes of Denaturation Solution and 1× Washing
Buffer (Biotage). A PSQ Low Sequencing Plate was prepared with 1× Annealing Buffer
(Biotage) and 20 pmoles of the appropriate sequencing primer in each well. The captured beads
containing biotinylated DNA strands were dispersed into the wells and annealing with
sequencing primer was allowed to proceed for 5 min at 95°C. The plate was cooled for 10 min
at room temperature and then placed into the PSQ 96 MA Pyrosequencer (Biotage) along with
a dispensing cartridge containing Enzyme Mixture, Substrate Mixture and dNTPs from a
PyroGold Reagents Kit. Sequencing was performed and allele determination was performed
with the Pyrosequencing Software.
Statistics/Planned Analyses
As previous data pertaining to CYP2C9 genotype and pharmacodynamic responses was not
available from the CKD population, a priori statistics were not conducted. Based on a review
of several published studies that reported CYP2C9 genotype frequencies, it was assumed that
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our CKD cohort of fifty-nine Caucasian patients would be sufficient for an initial evaluation
on pharmacodynamic responses to losartan therapy. [6,15]
Since kidney function as defined by urinary protein quantification and/or eGFR is/are
commonly used in assessing the clinical benefits of drugs on the kidneys, we were interested
in the association between the presence or absence of a variant CYP2C9 allele and changes in
urinary protein excretion, eGFR, and serum creatinine. Additionally, since blood pressure can
effect kidney disease progression and losartan can reduce blood pressure, changes in systolic
and diastolic blood pressures according to CYP2C9 genotype were also evaluated. The
analyses by kidney disease groupings were included since variability in the response to
therapies can be influenced by the type of the disease itself and this grouping system would
increase the homogeneity of the evaluated populations. [16,17] Differences between baseline
and six-month follow-up measures (delta values) in clinical variables (urinary protein
excretion, eGFR, serum creatinine, SBP, and DBP) were assessed according to the presence
or absence of a CYP2C9 allelic variant by either a two-tailed t-test or nonparametric equivalent
(Mann Whiney U test). Fisher’s Exact Test was used to compare frequencies of prescribed
diuretics, angiotensin converting enzyme inhibitors, and “other” medications between groups.
All tests were two-tailed with an alpha value set at <0.05. Statistical analyses were conducted
using Instat 3.05 (San Diego, CA).
Results
Demographics (mean ± SD) for the fifty-nine patients included age (53 ± 18 yrs), weight (84.0
± 22 kg), and 64% female. Sixty-one percent of patients (n = 36) were classified as having a
primary renal disease (e.g. glomerulonephritis) and the remaining 39% (n = 23) had secondary
causes of renal disease (e.g. type II diabetes mellitus, hypertension). The mean ±SD baseline
losartan dosage in the primary (59±31 mg/day) and secondary (60±26 mg/day) renal disease
groups were similar. For patients included in the secondary renal disease grouping, 25% and
78%, respectively had a diagnosis of type II diabetes mellitus and hypertension (with overlap
in one patient). Similar frequencies of diuretic, angiotensin converting enzyme inhibitor and
“other” blood pressure agents were prescribed at baseline and follow-up within and between
each chronic kidney disease category.
The frequencies for the CYP2C9 allelic determinations at amino acid positions 144 (Arg to
Cys) and 359 (Ile to Leu) and subsequent genotypes are shown in Table 1. We observed an
allelic frequency of 5% for the *2 allele and a frequency of 6% for the *3 allele in our sample
population. As shown in Table 1, the combined frequency of having a heterozygous genotype
for one of the variant *2 or *3 alleles was 20%, while the frequency of having a homozygous
or heterozygous mutant genotype (*2/*2, *2/*3, or *3/*3) was 2% and in this study was
comprised of only the *2/*3 genotype. This data was in agreement with Hardy Weinberg
equilibrium.
Baseline (pre-losartan) values for the clinical outcome parameters were generally similar
within renal disease groups. (Table 2) There was, however, a trend in the primary renal disease
grouping to have greater daily urinary protein excretion at baseline (p=0.07) in wildtype
patients. Since this trend was recognized, the percentage change in urinary protein excretion
was also calculated and compared. Differences in body weight trended toward higher values
in variant groung of the primary renal disease category (96.8±13.7 kg) than the wildtype group
(81.3±20.6 kg) p=0.05. No differences in baseline measures between wildtype and variant
groups were appreciated within the secondary kidney disease group. Baseline systolic (156mm
Hg) and diastolic (93mm Hg) blood pressure values for the *2/*3 subject (in the primary renal
disease group) were higher than the mean values in the variant group as a whole. Baseline Scr
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(2.0mg/dL) was within the range for the variant group and UP (160mg/day) was low for the
variant group for the lone *2/*3 subject.
The changes in clinical parameters from baseline to follow-up were computed (denoted as delta
values) and compared in each kidney disease group (primary and secondary) according to the
presence or absence of variant CYP2C9 alleles.(Table 3) In the primary kidney disease, e.g.
glomerulonephritis, group there were no statistically significant differences in the clinical
parameter changes from baseline to follow-up. However, the delta (−1278±4277 vs −458±1651
mg/day, p=0.14) and % delta (−125±323 vs −31.7±156%, p=0.12) urinary protein excretion
exhibited a trend toward more improvement in the wildtype vs variant genotype groups,
respectively. In the secondary renal disease, e.g. Type II diabetes mellitus and hypertension,
group there was a statistically significant difference in the SBP (16.2±27.1 mm Hg vs −5.5
±17.5 mm Hg; p=0.04) in the variant vs wildtype groups. A similar trend in diastolic blood
pressure was appreciated (9.8±16.0 mm Hg vs −3.2±10.6 mm Hg; p=0.05) in the variant versus
wildtype groups, respectively. The change in systolic (−23mm Hg) and diastolic (−16mm Hg)
blood pressure values for the *2/*3 subject were greater than the mean values in the variant
group. The change in Scr (−0.5mg/dL) was within the range for the variant group and UP
(+76mg/day) was increased for the variant group for the lone *2/*3 subject.
Discussion
Our results generally supported the a priori hypothesis of this study that CKD patients with
the CYP2C9 *2 and *3 allelic variants would have associated attenuated clinical effects of
losartan as opposed to patients classified as wildtype. In order to provide homogeneity to our
population, we assessed CYP2C9 genotype and pharmacodynamic outcomes to losartan
according to primary and secondary kidney disease grouping. In the primary kidney disease
group, there was a trend toward more improvement in urinary protein excretion in the presence
of the *1/*1 genotype versus genotypes comprising the *2 and/or *3 alleles. No trends in
improvements in blood pressure or eGFR were suggested. These results are encouraging for
patients with glomerulonephritis, who often have moderate to significant proteinuria with
minimal to mild baseline alterations in blood pressure. However, in the patients with secondary
kidney diseases (e.g. Type II diabetes mellitus and hypertension), there were clinically
significant reductions in DBP and SBP in wildtype patients and actual increases in blood
pressure in the *2 and *3 variant group. In secondary kidney disease, improvements in eGFR
and urinary protein excretion were not appreciated. This differential improvement on blood
pressure in a group of CKD patients who often have moderate to significant hypertension, with
minimal proteinuria reflects some beneficial targeting of responses.
The results of this study are important for patients with primary kidney diseases where disease-
specific treatments are lacking. A key treatment strategy is reduction in proteinuria as this has
been suggested to reduce eGFR decline. [1] As suggested by our results, variants in CYP2C9
may be at least partially responsible for less than optimal antiproteinuric effects in patients
receiving losartan therapy. Although the results are encouraging, evaluation of additional
patients with primary kidney diseases will be required to validate statistical significance
between wildtype vs CYP2C9 variant genotypes and proteinuria reduction. As dosages of
losartan were similar in the primary kidney disease patients with and without the CYP2C9
variants, dosage-related effects are less likely. However, as patient weights were higher in the
variant group and we did not measure plasma concentrations, it is conceivable that the achieved
losartan plasma concentrations may have been lower in the variant group, possibly reducing
the probability of a response. Since the prescription frequencies for angiotensin converting
enzyme inhibitors, diuretics, and “other” blood pressure medication prescriptions were similar
between genotype groups, these medications were not likely contributory in differential
responses. As an adequate anti-proteinuric response to losartan therapy is of paramount
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importance in the first 6–12 months of therapy, future determination of CYP2C9 genotype,
prior to prescribing medications, may be useful to help predict which patients are more likely
to have the greatest impact on urinary protein reduction.
Regarding the clinical outcomes in patients with secondary kidney diseases, our results showed
reductions in SBP and DBP in patients in the CYP2C9 wildtype group as compared to the
variant group. Secondary kidney diseases are defined by diseases that affect the kidney as a
complication of their long-duration and poor control; e.g. Type II diabetes mellitus and
hypertension. Since the frequencies of angiotensin converting enzyme inhibitors, diuretics, and
“other” blood pressure medication usage were similar between the variant and wildtype groups,
these medications were likely not related to any genotype differences. Our finding of favorable
blood pressure effects is significant as in both type II diabetes mellitus and hypertension, blood
pressure control is of paramount importance in preventing and/or slowing chronic kidney
disease progression to end stage kidney disease. A previous study in a homogeneous population
of Type I diabetic patients with nephropathy demonstrated a significant reduction in SBP (p =
0.001) after four months of losartan therapy in patients who did not carry the *3 variant alleles
as opposed to those who were carriers. [16] The effects of the *2 variant on blood pressure
were not reported and in fact, the authors grouped the *2 variant in with the wildtype patients
for their analysis. While the authors provided no rationale for their decision to group in the
manner that they did, it is curious given the previously published study results by Lee, et al.
that described alterations in E-3174 formation clearance in both the *2 and *3 allelic variants.
[18] A previous study that evaluated the association between another CYP2C9 substrate (e.g.
tolbutamide) and genotype reported prolonged half-life in subjects whose genotypes exhibited
the *3 allele, but not the *2 allele. [19] Hence, although grouping the *2 allele in with the
wildtype vs the *3 group would be justified for tolbutamide analysis, it unclear at this point
that this is the correct strategy for losartan analyses. However, Babaoglu et al, reported an
increase in losartan to E3174 in the CYP2C9 *1/*3 group that was statistically greater than the
*1/*2 or *1/*1 groups. [20] The study by Babaoglu (losartan) [20] and Kirchheiner
(tolbutamide) [19] are similar in that they both show a moderate effect of *2 and major effect
of *3 on outcome. The lack of a statistically significant effect in the Babaoglu study is likely
secondary to a statistical phenomenon. e.g. while there were similar number of patients in the
*1/*3 (n=12) and *1/*2 (n=10) groups, a larger effect (*3) would result in a significant value
with smaller patient numbers than would a moderate effect (*2). Caution, should thus be
exercised when grouping patients by genotype for analyses across different substrates for drug
metabolizing enzymes.
Regarding blood pressure effects, the clinical significance of the CYP2C9 *2 and *3
polymorphisms in patients prescribed another CYP2C9 substrate and angiotensin receptor
blocker (irbesartan) has also been reported. [10] Irbesartan, contrary to losartan requires
CYP2C9 for conversion to an inactive metabolite. In this study, carriers of the *2 variant
CYP2C9 allele experienced almost twice the reduction in both systolic and diastolic blood
pressure compared to individuals with the wild-type genotype. [10] However, these
investigators did not have sufficient patients with the *3 allelic variant to enable evaluation of
the contribution of this variant on blood pressure responses. The results of the study suggest
that the *2 allelic variant subjects had reduced catalytic activity of CYP2C9 as compared to
wildtypes, resulting in an enhanced blood pressure lowering response.
While we did not perform pharmacokinetic assessments in our study, two previous publications
addressed the association between CYP2C9 genotype and losartan pharmacokinetics in healthy
subjects. [7,8,18] Using an in vitro approach, Yasar et al. found that in human liver microsomes
from a healthy liver bank, the rates of formation for losartan’s active metabolite (E-3174) were
significantly lower and the intrinsic clearance of losartan was reduced (mainly explained by a
lower Vmax) in carriers of at least one CYP2C9 variant allele (*2 or *3) as compared to
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microsomes representing homozygosity for the wild-type genotype. [7] An in vivo by the same
group showed a reduction in the maximum E-3174 plasma concentration in individuals with
the CYP2C9 *1/*3 and *2/*3 genotypes vs wildtypes and even lower E-3174 plasma
concentration in the CYP2C9 *3/*3 genotype. [8] The effects from the *1/*2 and *2/*2
genotypes were not able to be appropriately evaluated secondary to these subject groups being
comprised of less than five patients each. A small pharmacokinetics study by Lee et al[18]
reported no pharmacokinetic differences between CYP2C9 wildtypes and *1/*2 and *1/*3 in
healthy volunteers receiving losartan. However, the formation clearance of E-3174 by the
CYP2C9 *1/*2 genotypes was reduced as compared to the wildtype, with no differences
appreciated in subjects with the *1/*3 genotype. Unlike the previous study, each genotype
group was comprised of five patients, allowing appropriate statistical testing. No significant
changes in blood pressures (SBP or DBP) between genotype groups were reported. [18] Effects
on the parent to metabolite ratio supporting reduced formation of the E-3174 metabolite has
also been reported for the CYP2C9 *1/*3 vs wildtype homozygotes in healthy Turkish and
Japanese subjects. [20,21] Based on the results supporting a role for both CYP2C9 *2 and *3
variants in modifying the formation clearance of E-3174 we felt that inclusion of our *2 patients
in the variant versus wildtype grouping was appropriate.
While our study is encouraging for clinicians who care for patients with primary and secondary
kidney diseases, there were several limitations that require disclosure. The study itself was
designed to evaluate trends in the effects of CYP2C9 allelic variants vs wildtype homozygotes
on clinical outcomes to losartan therapy. Hence by design, the study was limited in terms of
statistical power. We also did not assess pharmacokinetics since other studies that evaluated
losartan did not report significant changes in traditional pharmacokinetic parameters (area
under the curve, half-life, and oral clearance) based on genotype. However, the formation
clearance of E-3174 was reported to be reduced in the CYP2C9 variants evaluated, yet one of
these studies reported improvements in blood pressure as a clinical measure. Hence, there may
not be a direct and predictable relationship between traditional pharmacokinetic variables and
pharmacodynamic measures such as blood pressure and urinary protein excretion with losartan.
A role of variations in additional rare CYP2C9 alleles and ACE insertion/deletion genotype on
clinical response to losartan therapy cannot be ruled-out as these genes were not assessed.
Several newly recognized rare CYP2C9 alleles have been discovered and in vitro studies
suggest reduced catalytic activity toward tolbutamide (another CYP2C9 substrate). [9,22]
However, many of these alleles are found in racial groups other than Caucasians and this makes
it unlikely that they would contribute to the results of this study. The existing published data
does not support a role of ACE insertion/deletion genotype on responses to losartan therapy.
[23–25]
Conclusions
The results of this study demonstrated that there was a trend in reduction of urinary protein
excretion in patients with primary kidney disease (comprised of glomerular diseases) receiving
losartan when the CYP2C9 *2 or *3 variants were absent. Patients with secondary kidney
diseases tended to have significant reductions in DBP and SBP with losartan therapy when
they were classified as CYP2C9 wildtype vs CYP2C9 variants. These preliminary results
support future studies in larger numbers of patients with CKD to fully understand the role of
CYP2C9 genotype on clinical outcomes such as proteinuria and blood pressure in losartan-
treated patients.
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Table 1
CYP2C9 Allelic and Genotype Distributions
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Table 2
Baseline Demographic and Clinical Measures by Disease Classification









Age (yrs) 43.5 (17.8) 49.9 (15.7) 64.2 (14.1) 67.4 (8.05)
Weight (kg) 83.1 (20.6) 96.8 (13.7)+ 89.7 (24.6) 71.7 (23.4)
Gender (%female) 65% 86% 50% 80%
Losartan dose (mg/day) 56 (29) 67 (38) 63 (29) 50 (0)
SBP (mm Hg) 131 (20.5) 136 (12.8) 141 (17.4) 128 (13.2)
DBP (mm Hg) 75.3 (9.77) 82.5 (6.57) 73.5 (13.0) 67.4 (14.8)
SCr (mg/dL) 1.63 (0.81) 1.57 (0.69) 2.03 (0.71) 2.04 (1.20)
eGFR (mL/min/1.73m2) 41.6 (22.8) 36.2 (15.9) 30.2 (14.4) 29.8 (19.4)
UP (mg/day) 2632 (4710) 1365 (3061)* 2051 (2694) 340 (232)





DBP – diastolic blood pressure; eGFR – estimated glomerular filtration rate via Modification of Diet in Renal Disease equation [14], SBP – systolic
blood pressure; SCr – serum creatinine, UP – urinary protein to creatinine ratio, WT = wildtype Variant = presence of a *2 and/or *3 allele
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Table 3







Δ SBP (mm Hg) −3.6 (26.3) −1.7 (14.2) 0.863
Δ DBP (mm Hg) −0.2 (13.8) −1.2 (13.8) 0.879
Δ SCr (mg/dL) 0.2 (0.6) 0.2 (0.8) 0.606
Δ eGFR (mL/min/1.73m2) 6.5 (13.6) 8.5 (14.5) 0.734
Δ UP (mg/day) −1278 (4277) −458 (1651) 0.139
Δ % UP −125 (323) −31.7 (156) 0.123







Δ SBP (mm Hg) −5.5 (17.5) 16.2 (27.1) 0.044
Δ DBP (mm Hg) −3.2 (10.6) 9.8 (16.0) 0.043
Δ SCr (mg/dL) −0.02 (0.5) −0.3 (0.9) 0.530
Δ eGFR (mL/min/1.73m2) 2.7 (8.7) 5.2 (11.6) 0.493
Δ UP (mg/day) −1161 (2192) −5.7 (210) 0.611
Δ %UP −67.3 (121) 1.4 (106) 0.521
Δ Dose (mg) 15.3 (24.5) 20.0 (27.4) 0.793
Data are presented as mean (standard deviation)
DBP – diastolic blood pressure; eGFR – estimated glomerular filtration rate via Modification of Diet in Renal Disease equation [14], SBP – systolic
blood pressure; SCr – serum creatinine, UP – urinary protein to creatinine ratio, WT = wild type Variant = presence of a *2 and/or *3 allele
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